SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing robust vehicle deliveries for December and the fourth quarter, reaching new highs and demonstrating significant annual growth. The community is actively discussing the potential for imminent profitability, buoyed by strong sales performance and recently extended government subsidies favoring NEVs, positioning NIO ahead of its Chinese counterparts. Despite positive operational momentum, many investors are capitalizing on price dips, anticipating a strong market response as the company's fundamentals continue to improve.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to its strategic sale of Bressner Technology, which has boosted its cash reserves and sharpened its focus on core AI and edge computing. The community is actively discussing the company's recent stronger-than-expected earnings and raised guidance, alongside high anticipation for a significant military contract for 360 situational awareness systems. Many investors view OSS as an undervalued pure-play in the growing Edge AI and defense sectors, highlighting its tight float and institutional interest.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is drawing significant attention following robust Q3 earnings and strategic moves to bolster its ETF business through acquisitions, alongside its prominent role in a rebounding M&A market. The community is actively discussing the stock's impressive run and strategic AI integration efforts, with many anticipating continued strength, while others debate its high valuation and the potential for a stock split.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending amid intense frustration as the biotech sector's (XBI) extended bullish rally continues to defy expectations, leading to significant pressure on this 3x leveraged bear ETF. The community is sharply divided, with many anticipating an imminent, overdue reversal due to XBI's stretched technicals and high RSI, while others caution against fighting the sector's persistent upward momentum.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following the FDA's acceptance of its sNDA for AXS-05 in Alzheimer's disease agitation with Priority Review, setting a PDUFA target in April 2026. This significant regulatory clarity, coupled with positive updates for AXS-12 in narcolepsy and continued strong Auvelity script growth, is fueling widespread optimism among investors. The community is celebrating substantial long-term gains and actively discussing AXSM's potential to become a major CNS powerhouse, anticipating further analyst upgrades and robust performance as the company advances its diverse pipeline and commercial footprint.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed interim Phase 2 results for its ARCT-032 cystic fibrosis therapy, which showed signs of mucus plug reduction but limited lung function improvement, leading to significant stock volatility. Community sentiment is divided, with many viewing the sharp decline as an overreaction and highlighting the therapy's biological activity, the strength of their mRNA platform, other pipeline assets, and a high-stakes trade secret lawsuit against AbbVie as key discussion points for future value. Simultaneously, discussions around their influenza vaccine candidates are gaining traction amidst concerns over emerging flu variants.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending as its directors and officers extended their share lock-up until September 2026, signaling strong insider confidence and aligning with promising preliminary Phase 3 trial data showing a significant reduction in breast cancer recurrence. The community is actively discussing a potential short squeeze, fueled by an extremely high cost-to-borrow and limited shares available, while long-term investors anticipate a strategic transaction or significant valuation re-rating for this low-float biotech.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals is trending due to the accumulating global regulatory approvals for EKTERLY, its innovative oral on-demand hereditary angioedema treatment, with Japan being the latest market. The community is actively discussing the drug's strong initial sales performance and its significant market advantage as the first oral option, fueling optimism for its global commercialization. Analysts are reinforcing bullish sentiment, recognizing the company's trajectory towards profitability and its strategic position within the biotech sector, with many anticipating further upside.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is currently trending following key regulatory approvals for its Renergen acquisition and new "Overweight" analyst coverage with a bullish price target. Despite these positive developments, community discussion reflects significant frustration over perceived management missteps, repeated commercial shipment delays, and ongoing dilution concerns. This creates a polarized sentiment, balancing long-term potential in critical isotope markets against short-term execution challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Silver futures for March 2026 delivery climbed 1.4% on Monday.</li><li>Spot gold prices rose to the highest since October 21.</li><li>The dollar index fell back below 50-DMA for the first time since October 17.</li></ul>&nbsp;Precious metals surged on Monday, with spot silver (XAG/USD) scaling record highs while spot gold (XAU/USD) reached its highest level since October 21.On Monday, spot silver climbed above $58 per ounce for the first time. At the time of writing, it was up more than 3.1%. While there have been two separate pullbacks over the past month, spot prices continue to remain well above the 50-day moving average (50-DMA).Silver prices are on track for a sixth straight session of gains. On Friday, the XAG/USD pair climbed past $55 an ounce for the first time, buoyed by a weak dollar as traders increased their bets on a potential Fed rate cut on December 10. Recent comments from top Fed officials, along with weaker post-shutdown economic data, have reinforced market expectations for a rate cut next month.Data from the CME FedWatch tool showed an 87.4% probability of a 25-basis-point rate cut at the December 10 meeting. A week back, the figure stood slightly lower at 84.4%.Silver futures maturing in March 2026 delivery climbed 1.4%, on track to gain for a seventh straight session.<h2 class="st-heading-2">Physical Silver Supply Challenges</h2>According to veteran commodities expert and Head of Commodity Strategy for Saxo Bank, Ole Hansen, the current surge can be traced to a ‘historic tightening’ that began in London in October, the world’s primary hub for physical silver trading.In a Saxo Bank report on Monday, Hansen noted that London vaults had steadily depleted in recent months as the metal shipped out to meet strong demand from the U.S. and India. This has led to a sharp decline in “free-float” inventory, in which the metal is not tied to exchange-traded funds (ETFs), leases, or industrial contracts. As availability decreased, the cost of borrowing, known as the lease rate, jumped sharply, putting pressure on traders.<h2 class="st-heading-2">Gold And The Greenback</h2>Spot gold was up 0.5% at $4,237.5 per ounce on Monday, while gold futures for February 2026 delivery rose around 0.4%. The metal is trading well above its 50-DMA.On the other hand, the dollar slid yet again, with the U.S. Dollar Index (DXY) falling back to its 50-DMA for the first time since October 17.&nbsp;It has declined in five of the last six sessions. The DXY measures the greenback’s strength against a basket of six key currencies: the euro, Japanese yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc.&nbsp;Over the past six months, silver prices have shot up more than 77%, significantly above spot gold’s near 30% gains.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Spot Silver Surges Past $58 Per Ounce In Record-Breaking Rally

Spot silver prices have gained consecutively for a sixth session, buoyed by the potential rate cut bets.

Equity

<ul class="summary-bullets"><li>Hansen noted that to avoid triggering the bearish setup, silver needs to stay above $48.92 mark.</li><li>Over the last six months, silver prices have surged nearly 60%.</li><li>The expert noted that on the upside, if silver pulls back slightly and then rebounds around $51 per ounce, it would signal a strong bullish signal.</li></ul>&nbsp;Driven by concerns surrounding geopolitical turmoil, safe-haven assets have been drawing investor interest, as reflected in the sharp rise in gold and silver prices. Over the last six months, silver prices have surged nearly 60%, including a 10% jump this week.However, the spot silver chart suggests a double-top pattern, a formation that often precedes a downturn.In a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/Ole_S_Hansen/status/1989307599087432133">post on X</a> on Friday, veteran commodities expert and Head of Commodity Strategy for Saxo Bank, Ole Hansen, flagged key levels to watch out for.&nbsp;Hansen stated that to avoid triggering that bearish setup, silver needs to stay above $48.92 per ounce during this equity-driven risk-off phase. Ideally, prices should remain above the $ 50-per-ounce mark, Hansen added.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/Ole_S_Hansen/status/1989307599087432133"><img src="https://news.stocktwits-cdn.com/Ole_Hansen_png_b49f48973b.webp" alt="Ole Hansen.png"></a>At the time of writing, spot silver (<a href="https://stocktwits.com/symbol/XAGUSD">XAG/USD</a>) was down 3% at $50.70 per ounce.The expert noted that on the upside, if silver pulls back slightly and then rebounds around $51 per ounce, it would signal a strong bullish signal.<h2 class="st-heading-2">Silver Leads Commodities Rally</h2>In a Saxo Bank report on Friday, Hansen noted the Bloomberg Commodity Index is heading for its best week since June and is up more than 15% this year, with nearly every major commodity category contributing to the rally, including precious metals, energy, grains, and industrial metals.&nbsp;Silver, natural gas, sugar, gold, and soybeans are among the top performers. This broad strength stands out against the weakness in tech stocks and crypto, he wrote. Silver prices are set to rise for the seventh consecutive month and for the ninth time in the past eleven months. On Thursday, silver prices jumped to an all-time high of $54.42 per ounce.Silver has significantly outperformed gold over the past six months, with 27.6% gains – more than double those of gold (<a href="https://stocktwits.com/symbol/XAUUSD">XAU/USD</a>).For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, one-ounce American Silver Eagle bullion coin is placed among one-ounce silver bullion coins

Is Silver's Recent Double-Top Formation Concerning? Ole Hansen Talks About Some Important Levels To Watch Out For

Over the last six months, silver prices have surged nearly 60%, including a 10% jump this week, but technical charts indicate potential resistance

SLVO offers the returns of a covered-call strategy comprising long shares of a physical silver ETF (SLV) and short 1-month call options with a strike price of 106% of SLV.

SLVO
Credit Suisse Silver Shares Cov Call ETN

Feed

News

Sentiment

Fundamentals

Info

Latest SLVO News

SLVOCredit Suisse Silver Shares Cov Call ETN